PMA device
VICI VENOUS STENT System
Boston Scientific Corporation · Stent, Iliac Vein (QAN, Class III) · First FDA decision May 2, 2019, newest Jun 29, 2021Pulmonary embolism and deep vein thrombosisVaricose veins and venous insufficiency
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
6
PMA pathway
Device trials
2
Naming "VICI VENOUS"
MAUDE reports
3
Brand "VICI VENOUS", since 2015
PubMed studies
11
Mentioning "VICI VENOUS"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing VICI VENOUS STENT System
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 6 of 6 decisions filed under this name.
- VICI VENOUS STENT SystemPMA supplement
P180013-S007 · Decided Jun 29, 2021 · 84 days after receipt · Normal 180 Day Track No User Fee
Device type: Stent, iliac vein (QAN) · Cardiology
- VICI VENOUS STENT System and VICI RDS Stent SystemPMA supplement
P180013-S006 · Decided Feb 11, 2021 · 204 days after receipt · Normal 180 Day Track No User Fee
Device type: Stent, iliac vein (QAN) · Cardiology
- VICI VENOUS STENT SystemPMA supplement
P180013-S005 · Decided May 26, 2020 · 47 days after receipt · Normal 180 Day Track No User Fee
Device type: Stent, iliac vein (QAN) · Cardiology
3 more FDA decisions with a free account
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "VICI VENOUS", any status and sponsor, newest update first.
Boston Scientific CorporationPublic (BSX)
NCT04856592 · 0 participants · Start Dec 31, 2021 · Primary completion Dec 31, 2022
Device: Boston Scientific Vici® Venous Stent System; Boston Scientific Opticross 35 Peripheral Imaging Catheter (OC35 catheter) · For: Chronic Venous Disorder; Venous Outflow Obstruction; Systemic Vein Outflow of Iliofemoral Vein
Boston Scientific CorporationPublic (BSX)
NCT02112877 · 200 participants · Start Jun 26, 2014 · Primary completion Dec 5, 2017
Device: Veniti Vici™ Venous Stent System · For: Chronic Venous Disorder; Venous Outflow Obstruction; Symptomatic Venous Outflow Obstruction of Iliofemoral Vein
Sites: Phoenix, Arizona; Scottsdale, Arizona; Little Rock, Arkansas · 24 sites in all
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "VICI VENOUS", and for the whole product code for context.
This brand
3 reports: 0 malfunction, 3 injury, 0 death
Whole product code QAN
1,334 reports: 763 malfunction, 563 injury, 8 death
Newest reports for this brand
- VICI VENOUS STENT SYSTEMInjury
MW5106402 · Received Dec 30, 2021 · Event dated Sep 18, 2020 · 1 other device named on this report
Device type: Stent, Iliac Vein (QAN)
Device problem as coded: Fracture; Obstruction of Flow
Patient problem as coded: Insufficient Information
- VICI VENOUS STENTInjury
MW5103609 · Received Aug 30, 2021 · Event dated Mar 22, 2021
Device type: Stent, Iliac Vein (QAN)
Device problem as coded: Migration or Expulsion of Device
Patient problem as coded: Nerve Damage; Paralysis
- VENITI VICI VENOUS STENTInjury
3009865301-2015-00001 · Received Jul 30, 2015 · Event dated Jun 15, 2015
Device type: Stent, Iliac (NIO)
Device problem as coded: Collapse; Fracture
Patient problem as coded: Pain; Swelling
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
- VICI VENOUS STENT System Product Usage: is intended for the treatment of obstructions and occlusions in the venous vasculature.Open, Classified
Z-1591-2021 · Started Apr 12, 2021
Reason given: The firm has received reports of stent migration after implantation
Cause as FDA categorized it: Under Investigation by firm · Device type: Stent, Iliac Vein (QAN)
Z-1592-2021 · Started Apr 12, 2021
Reason given: The firm has received reports of stent migration after implantation
Cause as FDA categorized it: Under Investigation by firm · Device type: Stent, Iliac Vein (QAN)
Published research
The most relevant PubMed records for "VICI VENOUS"[tiab]. The summary above synthesizes these.
- Venous Stents: Current Status and Future Directions.
Shamimi-Noori SM, Clark TWI · Tech Vasc Interv Radiol · 2018Review
- Device profile of the Vici venous stent for chronic iliofemoral venous obstruction recanalization: overview of its safety and efficacy.
Kingdon J, Gwozdz AM, Morris R, et al. · Expert Rev Med Devices · 2020Review
- Endovascular management of symptomatic deep vein thrombosis with combined approach.
Gallicchio V, Barbarisi D, Sciarrillo R, et al. · Clin Case Rep · 2021Case Reports
- The Vici venous stent for treatment of renal vein entrapment.
Cubberley AT, Hamandi M, Rawitscher C, et al. · Proc (Bayl Univ Med Cent) · 2021Case Reports
- The initial report on 1-year outcomes of the feasibility study of the VENITI VICI VENOUS STENT in symptomatic iliofemoral venous obstruction.
Razavi M, Marston W, Black S, et al. · J Vasc Surg Venous Lymphat Disord · 2018Clinical Trial, Multicenter Study
- Two Year Outcome After Chronic Iliac Vein Occlusion Recanalisation Using the Vici Venous Stent®.
Black S, Gwozdz A, Karunanithy N, et al. · Eur J Vasc Endovasc Surg · 2018
- Retrograde Carotid Stenting Using Newly Released Venous Stent for Cerebral Malperfusion in Type A Aortic Dissection.
Mukherjee D, Lewis E, Spinosa D, et al. · J Endovasc Ther · 2022Case Reports
- Midterm and Long-Term Outcomes following Dedicated Endovenous Nitinol Stent Placement for Symptomatic Iliofemoral Venous Obstruction: Three- to 5-Year Results of the VIRTUS Study.
Razavi MK, Gagne P, Black S, et al. · J Vasc Interv Radiol · 2022Multicenter Study
- Pivotal Study of Endovenous Stent Placement for Symptomatic Iliofemoral Venous Obstruction.
Razavi MK, Black S, Gagne P, et al. · Circ Cardiovasc Interv · 2019Clinical Trial, Multicenter Study
- Dedicated venous stent placement across the thoracic outlet: will novel venous stents transform axillosubclavian vein thrombosis treatment paradigm?
Li GE, Umapathy MP, Shin DS, et al. · CVIR Endovasc · 2025
- Placement of closed-cell designed venous stents in a mixed cohort of patients with chronic venous outflow obstructions - short-term safety, patency, and clinical outcomes.
Lichtenberg M, Breuckmann F, Stahlhoff WF, et al. · Vasa · 2018
Other devices of this type
Also filed under product code QAN.
- Duo Venous Stent SystemPhilips Image Guided Therapy Corporation · PMA 2026
- Zilver Vena Venous Self-Expanding StentCook Ireland, Ltd. · PMA 2024
- Abre Venous Self-expanding Stent SystemMedtronic Vascular, Inc. · PMA 2022
- Venovo Venous Stent SystemBard Peripheral Vascular, Inc. · PMA 2021
- Venous WallstentBoston Scientific Corporation · PMA 2020
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.